BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31503426)

  • 1. A rare case of acquired immunodeficiency associated with myelodysplastic syndrome.
    Li J; Li J; Li J; Yao H; Liu F; Gusella JF; Shi X; Chen X
    Mol Genet Genomic Med; 2019 Nov; 7(11):e923. PubMed ID: 31503426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor-derived myelodysplastic syndrome after allogeneic stem cell transplantation in a family with germline GATA2 mutation.
    Sakata N; Okano M; Masako R; Tanaka A; Yamashita Y; Karasuno T; Imadome KI; Okada M; Sugimoto K
    Int J Hematol; 2021 Feb; 113(2):290-296. PubMed ID: 32865708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies.
    Dunbar AJ; Gondek LP; O'Keefe CL; Makishima H; Rataul MS; Szpurka H; Sekeres MA; Wang XF; McDevitt MA; Maciejewski JP
    Cancer Res; 2008 Dec; 68(24):10349-57. PubMed ID: 19074904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
    Zhang Z; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
    Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
    Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics.
    Heinrichs S; Kulkarni RV; Bueso-Ramos CE; Levine RL; Loh ML; Li C; Neuberg D; Kornblau SM; Issa JP; Gilliland DG; Garcia-Manero G; Kantarjian HM; Estey EH; Look AT
    Leukemia; 2009 Sep; 23(9):1605-13. PubMed ID: 19387468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML.
    Gondek LP; Tiu R; O'Keefe CL; Sekeres MA; Theil KS; Maciejewski JP
    Blood; 2008 Feb; 111(3):1534-42. PubMed ID: 17954704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of single-nucleotide polymorphism array-based whole-genome analysis and uniparental disomy in myelodysplastic syndrome.
    Ou Y; Yang Y; Yu H; Zhang X; Liu M; Wu Y
    Int J Lab Hematol; 2021 Oct; 43(5):1062-1069. PubMed ID: 33650312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays.
    Wang L; Fidler C; Nadig N; Giagounidis A; Della Porta MG; Malcovati L; Killick S; Gattermann N; Aul C; Boultwood J; Wainscoat JS
    Haematologica; 2008 Jul; 93(7):994-1000. PubMed ID: 18508791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of genome-wide analysis of copy number alterations and UPD in myelodysplastic syndromes using combined CGH - SNP arrays.
    Ahmad A; Iqbal MA
    Curr Med Chem; 2012; 19(22):3739-47. PubMed ID: 22680919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
    Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Childhood myelodysplastic syndrome.
    Chatterjee T; Choudhry VP
    Indian J Pediatr; 2013 Sep; 80(9):764-71. PubMed ID: 23912822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gain-of-function
    Tesi B; Davidsson J; Voss M; Rahikkala E; Holmes TD; Chiang SCC; Komulainen-Ebrahim J; Gorcenco S; Rundberg Nilsson A; Ripperger T; Kokkonen H; Bryder D; Fioretos T; Henter JI; Möttönen M; Niinimäki R; Nilsson L; Pronk CJ; Puschmann A; Qian H; Uusimaa J; Moilanen J; Tedgård U; Cammenga J; Bryceson YT
    Blood; 2017 Apr; 129(16):2266-2279. PubMed ID: 28202457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.
    Scott BL; Pasquini MC; Fei M; Fraser R; Wu J; Devine SM; Porter DL; Maziarz RT; Warlick E; Fernandez HF; Soiffer RJ; Alyea E; Hamadani M; Bashey A; Giralt S; Geller NL; Leifer E; Hourigan CS; Gui G; Mendizabal A; Horowitz MM; Deeg HJ; Horwitz ME
    Transplant Cell Ther; 2021 Jun; 27(6):483.e1-483.e6. PubMed ID: 33775615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
    Shimoni A; Robin M; Iacobelli S; Beelen D; Mufti GJ; Ciceri F; Bethge W; Volin L; Blaise D; Ganser A; Luft T; Chevallier P; Schwerdtfeger R; Koster L; de Witte T; Kröger N; Nagler A; Yakoub-Agha I
    Br J Haematol; 2021 Nov; 195(3):417-428. PubMed ID: 34514596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome.
    da Silva FB; Machado-Neto JA; Bertini VHLL; Velloso EDRP; Ratis CA; Calado RT; Simões BP; Rego EM; Traina F
    J Clin Pathol; 2017 May; 70(5):435-442. PubMed ID: 27836923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation Clearance after Transplantation for Myelodysplastic Syndrome.
    Duncavage EJ; Jacoby MA; Chang GS; Miller CA; Edwin N; Shao J; Elliott K; Robinson J; Abel H; Fulton RS; Fronick CC; O'Laughlin M; Heath SE; Brendel K; Saba R; Wartman LD; Christopher MJ; Pusic I; Welch JS; Uy GL; Link DC; DiPersio JF; Westervelt P; Ley TJ; Trinkaus K; Graubert TA; Walter MJ
    N Engl J Med; 2018 Sep; 379(11):1028-1041. PubMed ID: 30207916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet's disease harboring GATA2 mutation.
    Sato Y; Fukatsu M; Suzuki T; Sasajima T; Gunji N; Yoshida S; Asano N; Fukuchi K; Mori H; Takano M; Hayashi K; Takahashi H; Shirado-Harada K; Kimura S; Koyama D; Migita K; Ikezoe T
    Int J Hematol; 2023 Nov; 118(5):642-646. PubMed ID: 37084069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.